Clinically, HBXIP expression positively correlates with PD-L1 levels, and HBXIP knockdown significantly reduces tumor growth, underscoring the therapeutic relevance of the HBXIP–p300–PD-L1 axis. The gene discussed is CD274; the disease is neoplasm.